Notably, some delivery systems of Herceptin have been exploited and have shown enhanced anticancer efficacy on HER2+ breast tumor-bearing mouse models 21, 22, 60; however, as far as we know, their potential cardiotoxicity has not been reported, and in clinical practice, Herceptin is mainly used to prevent local relapse after surgery. This evidence concerns the gene ERBB2 and breast neoplasm.